Efficacy of NOAC reversal agent confirmed

Doctors can now be confident that at least one non-vitamin K oral anticoagulant (NOAC) has an effective antidote to prevent potential bleeds.

According to the final results from the industry-funded RE-VERSE AD trial, idarucizumab leads to the immediate reversal of the anticoagulant effect of dabigatran in patients in emergency situations. 

The findings from the study of